Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 14/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122279 | 0.94 | ALDH1A1 (0.43) | GRM2ALDH1A1PDE4BJAK2JAK1 | |
| SCHEMBL3129231 | 0.92 | PDE4B (0.38) | GRM2PDE4B | |
| SCHEMBL3118133 | 0.88 | NAPRT (0.45) | GRM2PDE4BLMNAPOLBMAPT | |
| SCHEMBL1157272 | 0.87 | MAPT (0.45) | GRM2ALDH1A1PDE4BLMNAPOLB | |
| SCHEMBL3207786 | 0.87 | TRPM8 (0.35) | GRM2PDE4BTRPM8 | |
| SCHEMBL3132285 | 0.83 | GRM2 (0.43) | GRM2ALDH1A1PDE4BLMNAPOLB | |
| SCHEMBL3199280 | 0.83 | PDE4B (0.36) | ALDH1A1PDE4BLMNAMAPTKMT2A | |
| SCHEMBL3203958 | 0.83 | HRH4 (0.37) | GRM2ALDH1A1PDE4BLMNAMAPT | |
| SCHEMBL3218633 | 0.83 | HRH4 (0.37) | GRM2PDE4BJAK2JAK1LMNA | |
| SCHEMBL1159028 | 0.82 | GRM2 (0.44) | GRM2PDE4BLMNAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | GRM2 3498/4885ALDH1A1 190/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.